Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Immediate early response 3 pseudogene (ENSG00000270960)
- Target
- ENSG00000270960
- Molecular classification
- Pseudogene
01
Overview
The Immediate early response 3 pseudogene (ENSG00000270960) is a non-functional genomic sequence highly similar to the Immediate Early Response 3 (IER3) gene but contains mutations and/or lacks necessary regulatory elements for protein-coding activity. Pseudogenes like this may have limited biological activity, potentially regulating their parent gene or related pathways via RNA-based mechanisms (such as microRNA decoy or siRNA production), but are generally not considered functional genes, therapeutic targets, or biomarkers in clinical practice[1][3][4].
- Other names
- Immediate Early Response 3 (IER3) pseudogeneIER3P
02
Mechanism of action
None applicable
03
Biological functions
May act as a non-coding RNA with potential regulatory effects on gene expression, e.g., as a microRNA decoy or source of regulatory siRNAsNo direct protein function; not involved in conventional signaling, transport, or enzymatic activity
04
Disease associations
No direct disease involvement established; some pseudogenes are studied for potential regulatory functions in cancer and gene silencing, but this is context-dependent and not universally accepted for all pseudogenes like IER3P
05
Safety considerations
None relevant—pseudogenes are not therapeutic targets, so have no safety profile in this context
06
Interacting drugs
None known or relevant for this pseudogene
07
Biomarkers
None established
Beyond the preview
Go deeper on Immediate early response 3 pseudogene (ENSG00000270960).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Immediate early response 3 pseudogene (ENSG00000270960).